355 results on '"Zabotti, A"'
Search Results
2. The Challenge of IBD-Related Arthritis Screening Questionnaires in Early and Predominantly Entheseal Phenotypes
- Author
-
Zabotti, Alen, Cabas, Nicola, Cacioppo, Sofia, Zoratti, Caterina, Giovannini, Ivan, Berretti, Debora, Luchetti, Michele Maria, De Vita, Salvatore, Quartuccio, Luca, Terrosu, Giovanni, and Marino, Marco
- Published
- 2024
- Full Text
- View/download PDF
3. From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis
- Author
-
Watad, Abdulla, Zabotti, Alen, Patt, Yonatan Shneor, Gendelman, Omer, Dotan, Arad, Ben-Shabat, Niv, Fisher, Lior, McGonagle, Dennis, and Amital, Howard
- Published
- 2024
- Full Text
- View/download PDF
4. Bimekizumab in Biologics-Refractory Psoriatic Arthritis: A Real-Life Analysis from a Combined Dermatology-Rheumatology Clinic
- Author
-
Zabotti A, Cabas N, Giovannini I, Guella S, Cereser L, Zuiani C, Stinco G, Quartuccio L, and Errichetti E
- Subjects
biologics ,bimekizumab ,psoriatic arthritis ,refractory. ,Dermatology ,RL1-803 - Abstract
Alen Zabotti,1 Nicola Cabas,1 Ivan Giovannini,1 Silvia Guella,1 Lorenzo Cereser,2 Chiara Zuiani,2 Giuseppe Stinco,3 Luca Quartuccio,1 Enzo Errichetti3 1Department of Medical and Biological Sciences, Rheumatology Institute, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy; 2Department of Medicine, Institute of Radiology, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy; 3Department of Medical and Biological Sciences, Dermatology Institute, Azienda Sanitaria Universitaria Friuli Centrale, Udine, ItalyCorrespondence: Enzo Errichetti, Institute of Dermatology, Department of Medical Area, University of Udine, Piazzale Santa Maria della Misericordia, 15, Udine, 33100, Italy, Tel +39 0432559822, Email enzoerri@yahoo.it
- Published
- 2024
5. The economic value of human milk from three cohort studies in Friuli Venezia Giulia, Italy
- Author
-
Zabotti, Benedetta, Buchini, Sara, Milinco, Mariarosa, Cattaneo, Adriano, Pani, Paola, and Ronfani, Luca
- Published
- 2024
- Full Text
- View/download PDF
6. From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis
- Author
-
Abdulla Watad, Alen Zabotti, Yonatan Shneor Patt, Omer Gendelman, Arad Dotan, Niv Ben-Shabat, Lior Fisher, Dennis McGonagle, and Howard Amital
- Subjects
Psoriasis ,Psoriatic arthritis ,Biological therapy ,Prevention ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Introduction Biologic therapies are licensed for both psoriasis (PsO) and psoriatic arthritis (PsA) with some electronic medical record data suggest that IL (Interleukin)-23 blockers might be more protective in PsA prevention than TNF blockers; however, the findings have been inconsistent. Higher Psoriasis Area and Severity Index (PASI) scores have also been linked to an increased PsA risk. To clarify these unresolved issues we investigated biologic agents, methotrexate, phototherapy, and topical therapy for PsA prevention in patients with psoriasis. Methods This retrospective cohort study analyzed data from 58,671 patients with psoriasis from the Israeli Meuhedet Health Services Organization database was evaluated for incident PsA. Patients were categorized on the basis of treatment: group 1, topical therapy; group 2, phototherapy; group 3, conventional disease-modifying antirheumatic drugs (cDMARDs; methotrexate); group 4, biologic DMARDs which was also stratified according to biologic class. Results The PsA incidence rate was lower in the biologic agents’ group versus the methotrexate group (HR 0.46 [95% CI 0.35–0.62]). The incidence rates per 100 person-years varied across biologic treatment groups, with the anti‑IL‑12/23 or anti‑IL‑23p19 group at 4.57, the anti-IL-17 group at 4.35, and the TNF inhibitor group at 2.55. No differences were found between various biological agents in terms of preventing PsA. The phototherapy group exhibited a higher PsA development rate than the topical therapy group (HR 1.85 [95% CI 1.65–2.07]). Conclusion Biological agents are more effective than methotrexate in reducing incident PsA in patients with psoriasis. This lower rate of PsA on topical therapy compared to phototherapy supports the importance of psoriasis severity as a risk factor.
- Published
- 2024
- Full Text
- View/download PDF
7. Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors
- Author
-
Errichetti, Enzo and Zabotti, Alen
- Published
- 2024
- Full Text
- View/download PDF
8. The economic value of human milk from three cohort studies in Friuli Venezia Giulia, Italy
- Author
-
Benedetta Zabotti, Sara Buchini, Mariarosa Milinco, Adriano Cattaneo, Paola Pani, and Luca Ronfani
- Subjects
Breastmilk ,Breastfeeding ,Monetary value ,Italy ,Pediatrics ,RJ1-570 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background The Mothers’ Milk Tool, developed and launched by the Australian National University and Alive & Thrive in 2022, allows to estimate the volume and value of breastmilk using prevalence rates of breastfeeding by month of age from birth to 36 months. The objective of this study was to obtain these estimates for three cohort studies conducted in a region of Italy. Methods Breastfeeding data from three cohort studies carried out in 1999, 2007 and 2016, with follow-up to 12, 24 and 36 months of 842, 400 and 265 children, respectively, were entered into the downloadable version of the tool. Breastfeeding rates charts and tables with estimates of breastmilk production and value for breastfeeding of children aged 0–36 months were produced. Results The rates of initiation of breastfeeding were similar in the three cohorts, while the rates of any breastfeeding at subsequent ages increased over the years. The volumes and values of breastmilk per child increased accordingly, from around 130 L (13,000 USD) in 1999, to 200 L (20,000 USD) in 2007, to 226 L (22,600 USD) in 2016. The percentage of lost breastmilk decreased from 67.7% to 55.4% to 43.7%, respectively. Overall, the 1507 mothers of the three cohorts produced an estimated 250,000 L of breastmilk for their children aged 0–36 months. At 100 USD per litre, this would add up to around 25 million USD. Conclusions Our study shows that the Mothers’ Milk Tool can be used to estimate per child volumes and values of breastmilk produced and lost at local levels, and to provide simple indicators of the effects of breastfeeding interventions using the percentage of lost breastmilk, where datasets on rates of breastfeeding by month of age are available. The results of such studies can be used to advocate for better and adequately funded programmes for the protection, promotion and support of breastfeeding.
- Published
- 2024
- Full Text
- View/download PDF
9. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage
- Author
-
Laure Gossec, Josef S Smolen, Alen Zabotti, Georg Schett, Abdulla Watad, Dennis G McGonagle, Annarita Tullio, Salvatore De Vita, Ivan Giovannini, Enzo Errichetti, Ilaria Tinazzi, Luca Quartuccio, Ettore Silvagni, Filippo Fagni, Gabriele De Marco, David Simon, and Michael Sticherling
- Subjects
Medicine - Abstract
Objective Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis.Methods Patients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts. The key outcome was new-onset PsA. Musculoskeletal symptoms including inflammatory and non-inflammatory symptoms before PsA diagnosis were collected. Occurrence of PsA was analysed with survival analysis and cumulative incidence functions (CIFs).Results 384 patients with PsO were included with a mean follow-up of 33.0 (±20.9) months. 311 of 384 (80.9%) had subclinical PsA with a PsA incidence rate of 7.7 per 100 patient-years. Subclinical PsA displayed a higher risk of PsA development compared with PsO (HR=11.7 (95% CI 1.57 to 86.7), p=0.016). The probability of new-onset PsA estimated by the CIF was 9.4% (95% CI 4.7% to 10.6%) at month 12 and 22.7% (95% CI 17.2% to 28.6%) at month 36. 58.9% of cases reported inflammatory symptoms in the months immediately prior to PsA diagnosis but prior non-inflammatory symptoms were evident in 83.9% prior to PsA diagnosis. Peripheral joint swelling was the predominant PsA presentation pattern (82.1%).Conclusions The probability of PsA development among subclinical PsA was relatively high, emphasising the importance of emergent musculoskeletal symptoms when aiming for PsA prevention. Joint swelling was the dominant feature in new-onset PsA, likely reflecting clinical confidence in recognising joint swelling.
- Published
- 2024
- Full Text
- View/download PDF
10. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study
- Author
-
Michele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, Alen Zabotti, Roberta Ramonda, Maria Sole Chimenti, Lorenzo Dagna, Nicoletta Luciano, Anna Piccinelli, Ivan Giovannini, Giovanni Striani, Nicola Boffini, Gilda Sandri, Niccolò Possemato, Ilenia Pantano, Devis Benfaremo, Carlo Salvarani, Francesco Ciccia, Carlo Selmi, and Gianluca Moroncini
- Subjects
Psoriatic arthritis ,Upadacitinib ,Clinical efficacy ,Real life ,Psoriasis ,Peripheral arthritis ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 weeks and identify clinical predictors of response, in a multicentric cohort of patients affected by PsA. Methods One hundred and twenty-six patients with PsA treated with UPA were enrolled in 10 Italian centres. UPA effectiveness outcomes, such as the proportion of patients with MDA status, DAPSA remission, and low disease activity, ASDAS-CRP inactive and low disease activity, and change from baseline in DAPSA and ASDAS-CRP scores, were evaluated every 12 weeks until week 24. The proportion of DAPSA minor, moderate, and major improvement, and ASDAS clinically important improvement (CII) and major improvement (MI) were considered as well. All treatment-related adverse events were collected during the observation period. Clinical predictors of MDA response at week 24 were evaluated through multivariate analysis. Results At baseline, 124/126 (98%) and 54/126 (43%) patients showed peripheral and axial involvement, respectively; 110 (87%) patients were intolerant or resistant to biologic DMARDs. At 24 weeks, MDA status, DAPSA remission, and ASDAS-CRP inactive disease were achieved in 47%, 23%, and 48% of patients, respectively. Minor, moderate, and major DAPSA improvement was observed in 67%, 39%, and 23%, respectively; while 65% and 35% achieved ASDAS-CRP CII and MI, respectively. The mean change from baseline was 15.9 ± 13.5 (p
- Published
- 2023
- Full Text
- View/download PDF
11. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study
- Author
-
Luchetti Gentiloni, Michele Maria, Paci, Valentino, Carletto, Antonio, Zabotti, Alen, Ramonda, Roberta, Chimenti, Maria Sole, Dagna, Lorenzo, Luciano, Nicoletta, Piccinelli, Anna, Giovannini, Ivan, Striani, Giovanni, Boffini, Nicola, Sandri, Gilda, Possemato, Niccolò, Pantano, Ilenia, Benfaremo, Devis, Salvarani, Carlo, Ciccia, Francesco, Selmi, Carlo, and Moroncini, Gianluca
- Published
- 2023
- Full Text
- View/download PDF
12. Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors
- Author
-
Enzo Errichetti and Alen Zabotti
- Subjects
Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
13. Structured report improves radiology residents’ performance in reporting chest high-resolution computed tomography: a study in patients with connective tissue disease
- Author
-
Lorenzo Cereser, Filippo Marchesini, Emma Di Poi, Luca Quartuccio, Alen Zabotti, Chiara Zuiani, and Rossano Girometti
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
PURPOSETo evaluate the performance of radiology residents (RRs) when using a dedicated structured report (SR) template for chest HRCT in patients with suspected connective tissue disease-interstitial lung disease (CTD-ILD), compared to the traditional narrative report (NR).METHODSWe retrospectively evaluated 50 HRCT exams in patients with suspected CTD-ILD. A chest-devoted radiologist reported all the HRCT exams as the reference standard, pointing out pulmonary fibrosis findings (i.e., honeycombing, traction bronchiectasis, reticulation, and volume loss), presence and pattern of ILD, and possible other diagnoses. We divided four RRs into two groups according to their expertise level. In each group, RRs reported all HRCT examinations alternatively with NR or SR, noting each report's reporting time. The Cohen's Kappa, Wilcoxon, and McNemar tests were used for statistical analysis.RESULTSRegarding the pulmonary fibrosis findings, we found higher agreement between RRs and the reference standard reader when using SR than NR, regardless of their expertise level, except for volume loss.RRs' accuracy for "other diagnosis" was higher when using SR than NR, moving from 0.48 to 0.66 in the novel group (p = 0.035) and from 0.44 to 0.80 in the expertise group (p < 0.001). No differences in accuracy were found between ILD presence and ILD pattern. The reporting time was significantly lower (p = 0.001) when using SR than NR.CONCLUSIONSR is of value in increasing the reporting of critical chest HRCT findings in the complex CTD-ILD scenario and should be used early and systematically during the residency.
- Published
- 2022
- Full Text
- View/download PDF
14. Asymptomatic sacroiliitis detected by magnetic resonance enterography in patients with Crohn's disease: prevalence, association with clinical data, and reliability among radiologists in a multicenter study of adult and pediatric population
- Author
-
Cereser, Lorenzo, Zancan, Giovanni, Giovannini, Ivan, Cicciò, Carmelo, Tinazzi, Ilaria, Variola, Angela, Bramuzzo, Matteo, Murru, Flora Maria, Marino, Marco, Tullio, Annarita, De Vita, Salvatore, Girometti, Rossano, and Zabotti, Alen
- Published
- 2022
- Full Text
- View/download PDF
15. Salivary Gland Ultrasound in Primary Sjögren’s Syndrome: Current and Future Perspectives
- Author
-
Lorenzon M, Spina E, Tulipano Di Franco F, Giovannini I, De Vita S, and Zabotti A
- Subjects
primary sjögren’s syndrome ,major salivary glands ,ultrasound ,lymphoma ,core needle biopsy. ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Michele Lorenzon,1 Erica Spina,1 Francesco Tulipano Di Franco,1 Ivan Giovannini,2 Salvatore De Vita,2 Alen Zabotti2 1Institute of Radiology, Department of Medicine, University of Udine, Udine, Italy; 2Rheumatology Clinic, Department of Medical and Biological Sciences, Azienda Sanitaria Universitaria Friuli Centrale c/o University of Udine, Udine, ItalyCorrespondence: Michele Lorenzon, Institute of Radiology, Department of Medicine, University of Udine, Udine, Italy, Tel +39 0432 559232, Email michele.lorenzon@gmail.comAbstract: Salivary gland ultrasound (SGUS) is the imaging modality of choice for the assessment of parotid and submandibular gland parenchyma. Being highly effective, non-invasive and easy to perform, SGUS has become increasingly popular among specialists in assessing salivary gland (SG) abnormalities, including those commonly found in primary Sjögren’s syndrome (pSS). SGUS may be useful in the assessment of pSS and its complications, the most serious being the development of non-Hodgkin’s lymphoma (NHL). SGUS may also be useful in the characterization and differential diagnosis of diffuse and focal abnormalities commonly associated with pSS, and may act as a guide for core-needle biopsy (CNB), an established, safe, and feasible technique, which provides enough viable tissue for the diagnosis and assessment of lymphoproliferative diseases of the SG. The combination of SGUS with other tools, such as sonoelastography and artificial intelligence (AI), could further improve the usefulness of SGUS in the management of pSS. In this perspective, we summarize current and future applications of SGUS in pSS.Keywords: primary Sjögren’s syndrome, major salivary glands, ultrasound, lymphoma, core needle biopsy
- Published
- 2022
16. Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
- Author
-
Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, and Girolomoni G
- Subjects
psoriatic arthritis ,psoriasis ,therapy ,prevention ,early intervention ,disease modification ,Dermatology ,RL1-803 - Abstract
Paolo Gisondi,1 Francesco Bellinato,1 Martina Maurelli,1 Davide Geat,1 Alen Zabotti,2 Dennis McGonagle,3 Giampiero Girolomoni1 1Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; 2Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital ‘Santa Maria della Misericordia’ c/o University of Udine, Udine, Italy; 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UKCorrespondence: Paolo Gisondi, Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, Verona, 37126, Italy, Email paolo.gisondi@univr.itAbstract: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients with psoriasis ranges widely between 6% and 42%. In most cases, PsA is preceded by skin involvement by an average time of 7– 8 years. In the complex patho-mechanisms involved in the transition from psoriasis to PsA, the gut and skin have been proposed as the sites of immune activation triggering or contributing to the development of PsA. In such a transition, a subclinical phase has been identified, characterized by enthesopathy where soluble biomarkers and imaging findings but no clinical symptoms are detectable. Recent studies have provided some evidence that timely treated psoriasis may reduce the risk of developing PsA.Keywords: psoriatic arthritis, psoriasis, therapy, prevention, early intervention, disease modification
- Published
- 2022
17. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
- Author
-
Laure Gossec, Annamaria Iagnocco, Xenofon Baraliakos, Daniel Aletaha, Josef S Smolen, Alen Zabotti, Dennis G McGonagle, Gabriele De Marco, Jenny Emmel, and Paulo Gisondi
- Subjects
Medicine - Abstract
Background Identifying subjects at risk of imminent psoriatic arthritis (PsA) would allow these subjects to participate in therapeutic interventions to delay or prevent PsA development.Methods A systematic literature review (SLR) was conducted in 2021 in Medline, Embase, PubMed, Central databases and international congress abstracts (PROSPERO CRD42022255102). All articles reporting the characteristics of patients transitioning from psoriasis (PsO) to PsA and from undifferentiated arthritis (UA) to PsA were included. Clinical and imaging characteristics were collated before PsA onset and at time of PsA diagnosis.Results Eighteen of 23 576 references evaluated for PsO/PsA transition were analysed; 14 were cohort studies, 2 case-control studies. Two SLRs were used to enrich the project but were not analysed per se. Of 7873 references focusing on UA to PsA, 3 studies were included. Meta-analysis was not possible due to excessive data heterogeneity. Patients with PsO who developed PsA often reported joint pain, joint tenderness and functional limitations. Arthralgia (PsO, n=669; incident PsA, n=99) was associated with subsequent PsA development. On imaging, subclinical enthesopathy (PsO=325; Incident PsA=39) appeared linked to later PsA development. At the time of PsA onset (incident PsA, N=214), peripheral arthritis, mainly oligo-arthritis (ie, the mean number of swollen joints ranged from 1.5 to 3.2), was the most frequent pattern of clinical presentation.Conclusions Joint pain, arthralgia and entheseal involvement detected by imaging were frequent in individuals with PsO at risk for imminent PsA. Very early PsA was mainly oligoarticular. This review informed a EULAR taskforce on transition to PsA.
- Published
- 2023
- Full Text
- View/download PDF
18. Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
- Author
-
Julio Ramírez, Pascal Richette, Alen Zabotti, Sarah Ohrndorf, Elke Theander, Marijn Vis, William Tillett, May Shawi, Wim Noël, Marlies Neuhold, Michel van Speybroeck, Miriam Zimmermann, and Alexa Kollmeier
- Subjects
Medicine - Abstract
Objectives Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients’ overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters using machine learning to analyse data from the phase III DISCOVER-1/DISCOVER-2 clinical trials.Methods Pooled data from bio-naïve patients with active PsA receiving guselkumab 100 mg every 8/4 weeks were retrospectively analysed. Non-negative matrix factorisation was applied as an unsupervised machine learning technique to identify PsA phenotype clusters; baseline patient characteristics and clinical observations were input features. Minimal disease activity (MDA), disease activity index for psoriatic arthritis (DAPSA) low disease activity (LDA) and DAPSA remission at weeks 24 and 52 were evaluated.Results Eight clusters (n=661) were identified: cluster 1 (feet dominant), cluster 2 (male, overweight, psoriasis dominant), cluster 3 (hand dominant), cluster 4 (dactylitis dominant), cluster 5 (enthesitis, large joints), cluster 6 (enthesitis, small joints), cluster 7 (axial dominant) and cluster 8 (female, obese, large joints). At week 24, MDA response was highest in cluster 2 and lowest in clusters 3, 5 and 6; at week 52, it was highest in cluster 2 and lowest in cluster 5. At weeks 24 and 52, DAPSA LDA and remission were highest in cluster 2 and lowest in clusters 4 and 6, respectively. All clusters improved with guselkumab treatment over 52 weeks.Conclusions Unsupervised machine learning identified eight PsA phenotype clusters with significant differences in demographics, clinical features and treatment responses. In the future, such data could help support individualised treatment decisions.
- Published
- 2023
- Full Text
- View/download PDF
19. Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
- Author
-
Zabotti, Alen, Giovannini, Ivan, McGonagle, Dennis, De Vita, Salvatore, Stinco, Giuseppe, and Errichetti, Enzo
- Published
- 2022
- Full Text
- View/download PDF
20. Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis.
- Author
-
Naredo, Esperanza, D'Agostino, Maria Antonietta, Terslev, Lene, Pineda, Carlos, Miguel, M. Isabel, Blasi, Joan, Bruyn, George A., Kortekaas, Marion C., Mandl, Peter, Nestorova, Rodina, Szkudlarek, Marcin, Todorov, Plamen, Vlad, Violeta, Wong, Priscilla, Bakewell, Catherine, Filippucci, Emilio, Zabotti, Alen, Micu, Mihaela, Vreju, Florentin, and Mortada, Mohamed
- Published
- 2024
- Full Text
- View/download PDF
21. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
- Author
-
Zabotti, Alen, De Lucia, Orazio, Sakellariou, Garifallia, Batticciotto, Alberto, Cincinelli, Gilberto, Giovannini, Ivan, Idolazzi, Luca, Maioli, Gabriella, Tinazzi, Ilaria, Aletaha, Daniel, De Vita, Salvatore, Marchesoni, Antonio, Smolen, Josef, Iagnocco, Annamaria, McGonagle, Dennis, and Caporali, Roberto
- Published
- 2021
- Full Text
- View/download PDF
22. Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
- Author
-
Pierluigi Macchioni, Antonio Marchesoni, Giovanni Ciancio, Gilda Sandri, Alen Zabotti, Gentiana Vukatana, Luca Montaguti, Mariacristina Focherini, Marcello Govoni, Amelia Spinella, Nazzarena Malavolta, Francesca Zuliani, Marco Bruschi, Fabio Mascella, and Carlo Salvarani
- Subjects
psoriatic arthritis ,ultrasonography ,minimal disease activity ,synovitis ,enthesitis ,Medicine (General) ,R5-920 - Abstract
BackgroundIn psoriatic arthritis (PsA), low disease activity as defined by the Minimal Disease Activity (MDA) index is considered a good treatment target. However, as MDA is based only on clinical findings, it might not capture pauci-symptomatic inflammation. Sensitive imaging such as ultrasound (US) might disclose residual inflammatory signs in PsA patients in MDA.MethodsIn this cross-sectional multicentre study, adult PsA patients on biologic treatment in MDA for at least 6 months were consecutively enrolled for a thorough clinical and US examination. Data collection included demographics, personal history, main patient's reported outcomes, clinical and US findings of joints, tendon sheaths, tendons, bursae, and entheses involvement. All centers performed the US investigation in B-mode and Power Doppler (PD)-mode using a similar US machine equipped with a 18–6 and 13–5 MHz multifrequency linear probe. Statistical analysis included comparisons between groups and correlation tests.ResultsThe 72 PsA patients enrolled in the study had a median duration of MDA of 12 (6–65) months. Overall, US examination revealed a low number of acute lesions. However, 54% of patients had at least one PD signal in the examined tissues. A joint or enthesis positive PD signal was found in about 19 and 24% of patients, respectively. Synovial hypertrophy, at least one acute entheseal lesions, and bursitis were the most common changes, detected in 41.7, 41.7 and 26% of patients, respectively.ConclusionsPsA patients in a stable state of MDA may still have residual inflammation in peripheral articular structures detectable by US examination.
- Published
- 2022
- Full Text
- View/download PDF
23. Deep learning segmentation of Primary Sjögren's syndrome affected salivary glands from ultrasonography images
- Author
-
Vukicevic, Arso M., Radovic, Milos, Zabotti, Alen, Milic, Vera, Hocevar, Alojzija, Callegher, Sara Zandonella, De Lucia, Orazio, De Vita, Salvatore, and Filipovic, Nenad
- Published
- 2021
- Full Text
- View/download PDF
24. Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases
- Author
-
Francis Berenbaum, Louise Falzon, Tanja A Stamm, Dieter Wiek, Christian Dejaco, Alen Zabotti, Johannes Knitza, Helena Canhão, Christina Duftner, Martin Krusche, Johannes WJ Bijlsma, Hana Smucrova, Chetan Mukhtyar, Yeliz Prior, Polina Pchelnikova, Aurélie Najm, Luca Quartuccio, Nina Østerås, Annette de Thurah, Silvia Piantoni, Sara Badreh, Yvette Meissner, Andréa Marques, Rinie Geenen, Tanja Stamm, Meghna Jani, Johannes Bijlsma, Philipp Bosch, Tim Pelle, Line Raunsbæk Knudsen, Nikolay Stoilov, Chetan B. Mukhtyar, Savia de Souza, and James M. Gwinnutt
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
25. Sjögren syndrome: looking forward to the future
- Author
-
Sara Zandonella Callegher, Ivan Giovannini, Sabine Zenz, Valeria Manfrè, Martin H. Stradner, Alojzija Hocevar, Marwin Gutierrez, Luca Quartuccio, Salvatore De Vita, and Alen Zabotti
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Primary Sjögren’s syndrome (pSS) is a heterogeneous disease characterised by a wide spectrum of manifestations that vary according to the different stages of the disease and among different subsets of patients. The aim of this qualitative literature review is to summarise the recent advances that have been reported in pSS, ranging from the early phases to the established disease and its complications. We analysed the diagnostic, prognostic, and management aspects of pSS, with a look into future clinical and research developments. The early phases of pSS, usually antedating diagnosis, allow us to investigate the pathophysiology and risk factors of the overt disease, thus allowing better and timely patient stratification. Salivary gland ultrasound (SGUS) is emerging as a valid complementary, or even alternative, tool for histopathology in the diagnosis of pSS, due to a standardised scoring system with good agreement and performance. Other promising innovations include the application of artificial intelligence to SGUS, ultrasound-guided core needle biopsy, and a wide array of novel diagnostic and prognostic biomarkers. Stratifying pSS patients through the integration of clinical, laboratory, imaging, and histopathological data; differentiating between activity-related and damage-related manifestations; and identifying patients at higher risk of lymphoma development are essential steps for an optimal management and individualised treatment approach. As new treatment options are emerging for both glandular and systemic manifestations, there is a need for a more reliable treatment response evaluation. pSS is a complex and heterogeneous disease, and many distinct aspects should be considered in the different stages of the disease and subsets of patients. In recent years, efforts have been made to improve our understanding of the disease, and certainly in the coming years, some of these novelties will become part of our routine clinical practice, thus improving the management of pSS patients.
- Published
- 2022
- Full Text
- View/download PDF
26. Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis
- Author
-
Maria Sofia Ciliento, Veronica Venturelli, Natale Schettini, Riccardo Bertola, Carlo Garaffoni, Giovanni Lanza, Roberta Gafà, Alessandro Borghi, Monica Corazza, Alen Zabotti, Sonia Missiroli, Caterina Boncompagni, Simone Patergnani, Mariasole Perrone, Carlotta Giorgi, Paolo Pinton, Marcello Govoni, Carlo Alberto Scirè, Alessandra Bortoluzzi, and Ettore Silvagni
- Subjects
psoriatic arthritis ,targeted therapies ,synovial biopsy ,fibroblast-like synoviocytes ,biological DMARDs ,targeted synthetic DMARDs ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The aims of this systematic literature review (SLR) were to identify the effects of approved biological and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on synovial membrane of psoriatic arthritis (PsA) patients, and to determine the existence of histological/molecular biomarkers of response to therapy. A search was conducted on MEDLINE, Embase, Scopus, and Cochrane Library (PROSPERO:CRD42022304986) to retrieve data on longitudinal change of biomarkers in paired synovial biopsies and in vitro studies. A meta-analysis was conducted by adopting the standardized mean difference (SMD) as a measure of the effect. Twenty-two studies were included (19 longitudinal, 3 in vitro). In longitudinal studies, TNF inhibitors were the most used drugs, while, for in vitro studies, JAK inhibitors or adalimumab/secukinumab were assessed. The main technique used was immunohistochemistry (longitudinal studies). The meta-analysis showed a significant reduction in both CD3+ lymphocytes (SMD −0.85 [95% CI −1.23; −0.47]) and CD68+ macrophages (sublining, sl) (SMD −0.74 [−1.16; −0.32]) in synovial biopsies from patients treated for 4–12 weeks with bDMARDs. Reduction in CD3+ mostly correlated with clinical response. Despite heterogeneity among the biomarkers evaluated, the reduction in CD3+/CD68+sl cells during the first 3 months of treatment with TNF inhibitors represents the most consistent variation reported in the literature.
- Published
- 2023
- Full Text
- View/download PDF
27. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.
- Author
-
Zabotti, Alen, Fagni, Filippo, Gossec, Laure, Giovannini, Ivan, Sticherling, Michael, Tullio, Annarita, Baraliakos, Xenofon, De Marco, Gabriele, De Vita, Salvatore, Errichetti, Enzo, Quartuccio, Luca, Silvagni, Ettore, Smolen, Josef S., Tinazzi, Ilaria, Watad, Abdulla, Schett, Georg, McGonagle, Dennis G., and Simon, David
- Published
- 2024
- Full Text
- View/download PDF
28. Safety, patient acceptance and diagnostic accuracy of ultrasound core needle biopsy of parotid or submandibular glands in primary Sjögren’s syndrome with suspected salivary gland lymphoma
- Author
-
Christian Dejaco, Alen Zabotti, Alojzija Hočevar, Chiara Zuiani, Salvatore De Vita, Ivan Giovannini, Sara Zandonella Callegher, Michele Lorenzon, Valeria Manfrè, Enrico Pegolo, Rossano Girometti, and Quartuccio Luca
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
29. The Digital Way to Intercept Psoriatic Arthritis
- Author
-
Ivan Giovannini, Philipp Bosch, Christian Dejaco, Gabriele De Marco, Dennis McGonagle, Luca Quartuccio, Salvatore De Vita, Enzo Errichetti, and Alen Zabotti
- Subjects
Psoriatic Arthritis (PsA) ,psoriasis ,technology ,prevention ,interception ,early diagnosis ,Medicine (General) ,R5-920 - Abstract
Psoriasis (PsO) and Psoriatic Arthritis (PsA) are chronic, immune-mediated diseases that share common etiopathogenetic pathways. Up to 30% of PsO patient may later develop PsA. In nearly 75% of cases, skin psoriatic lesions precede arthritic symptoms, typically 10 years prior to the onset of joint symptoms, while PsO diagnosis occurring after the onset of arthritis is described only in 15% of cases. Therefore, skin involvement offers to the rheumatologist a unique opportunity to study PsA in a very early phase, having a cohort of psoriatic “risk patients” that may develop the disease and may benefit from preventive treatment. Progression from PsO to PsA is often characterized by non-specific musculoskeletal symptoms, subclinical synovio-entheseal inflammation, and occasionally asymptomatic digital swelling such as painless toe dactylitis, that frequently go unnoticed, leading to diagnostic delay. The early diagnosis of PsA is crucial for initiating a treatment prior the development of significant and permanent joint damage. With the ongoing development of pharmacological treatments, early interception of PsA has become a priority, but many obstacles have been reported in daily routine. The introduction of digital technology in rheumatology may fill the gap in the physician-patient relationship, allowing more targeted monitoring of PsO patients. Digital technology includes telemedicine, virtual visits, electronic health record, wearable technology, mobile health, artificial intelligence, and machine learning. Overall, this digital revolution could lead to earlier PsA diagnosis, improved follow-up and disease control as well as maximizing the referral capacity of rheumatic centers.
- Published
- 2021
- Full Text
- View/download PDF
30. Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review
- Author
-
Fassio, A., Giovannini, I., Idolazzi, L., Zabotti, A., Iagnocco, A., and Sakellariou, G.
- Published
- 2020
- Full Text
- View/download PDF
31. An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study
- Author
-
Alen Zabotti, Michele Maria Luchetti, Carlo Francesco Selmi, Roberta Ramonda, Rosa Daniela Grembiale, Lorenzo Dagna, Salvatore D'Angelo, Giacomo Cafaro, Salvatore De Vita, Mara Felicetti, Silvia Marelli, Daniela Frigerio, and Ennio Giulio Favalli
- Subjects
spondyloarthritis ,peripheral spondyloarthritis ,axial spondyloarthritis ,psoriatic arthritis ,prospective study ,registry ,Medicine (General) ,R5-920 - Abstract
Introduction: Data about the clinical presentation and management of early and mild spondyloarthritis (SpA) are limited.Objectives: The objective of this study was to describe the baseline characteristics of disease-modifying antirheumatic drug (DMARD)-naïve patients with axial or peripheral SpA.Methods: The Spondyloarthritis Italian Registry: Evidence from a National Pathway (SIRENA) study is an ongoing, Italian, multicenter, prospective registry of patients with a first or newly confirmed diagnosis of SpA according to the Assessment of SpondyloArthritis International Society (ASAS) criteria. To be included, patients had to be naïve to conventional, targeted, and biological DMARDs for SpA. Patients were enrolled between June 2017 and June 2019 and classified into groups according to disease presentation: predominantly axial or peripheral manifestations. The study is ongoing, and patients are being followed for 2 years, with an evaluation every 6 months according to clinical practice. Differences in baseline demographics, lifestyle, and clinical characteristics between axial and peripheral SpA were evaluated.Results: In this study, 350 patients were enrolled, of which 123 (35.1%) were axial and 227 (64.9%) were peripheral patients. Patients with axial SpA were significantly younger at enrollment (median age: 44 vs. 53 years), had significantly more anxiety/depression (13 vs. 2.6%), and expressed higher disease activity compared to patients with peripheral SpA. Patients with peripheral SpA had significantly more cardiometabolic disorders (33 vs. 18.7%), skin psoriasis (65.2 vs. 21.1%), and nail psoriasis (35.5 vs. 17.1%) than patients with axial SpA. Dactylitis, enthesitis, and fibromyalgia were observed, respectively, in 17.6, 51.2, and 5.7% of patients with axial SpA and 24.3, 40, and 3.1% of patients with peripheral SpA. In both disease groups, women tended to report depression, joint tenderness, and higher disease activity more frequently than their male counterparts. At inclusion, a new diagnosis of SpA was performed in 58% of axial and 77% of peripheral patients, with a median time from symptom onset to diagnosis of 36 and 24 months, respectively. At baseline, most patients with axial SpA (77%) started a biological DMARD, while over half of the peripheral patients started a conventional DMARD.Conclusions: Based on a well-characterized clinical registry of SpA, we provided real-world insights on the clinical features of DMARD-naïve SpA patients, pointing out major differences between axial and peripheral disease in terms of clinical characteristics and treatment pattern. Future prospective evaluations within the SIRENA study will improve knowledge on SpA and contribute to defining the best therapeutic approach.
- Published
- 2021
- Full Text
- View/download PDF
32. High Throughput Genetic Characterisation of Caucasian Patients Affected by Multi-Drug Resistant Rheumatoid or Psoriatic Arthritis
- Author
-
Paola Tesolin, Francesca Eleonora Bertinetto, Arianna Sonaglia, Stefania Cappellani, Maria Pina Concas, Anna Morgan, Norma Maria Ferrero, Alen Zabotti, Paolo Gasparini, Antonio Amoroso, Luca Quartuccio, and Giorgia Girotto
- Subjects
rheumatoid arthritis ,psoriatic arthritis ,multi-drug resistance ,whole-exome sequencing ,SNPs-array ,HLA typing ,Medicine - Abstract
Rheumatoid and psoriatic arthritis (RA and PsA) are inflammatory rheumatic disorders characterised by a multifactorial etiology. To date, the genetic contributions to the disease onset, severity and drug response are not clearly defined, and despite the development of novel targeted therapies, ~10% of patients still display poor treatment responses. We characterised a selected cohort of eleven non-responder patients aiming to define the genetic contribution to drug resistance. An accurate clinical examination of the patients was coupled with several high-throughput genetic testing, including HLA typing, SNPs-array and Whole Exome Sequencing (WES). The analyses revealed that all the subjects carry very rare HLA phenotypes which contain HLA alleles associated with RA development (e.g., HLA-DRB1*04, DRB1*10:01 and DRB1*01). Additionally, six patients also carry PsA risk alleles (e.g., HLA-B*27:02 and B*38:01). WES analysis and SNPs-array revealed 23 damaging variants with 18 novel “drug-resistance” RA/PsA candidate genes. Eight patients carry likely pathogenic variants within common genes (CYP21A2, DVL1, PRKDC, ORAI1, UGT2B17, MSR1). Furthermore, “private” damaging variants were identified within 12 additional genes (WNT10A, ABCB7, SERPING1, GNRHR, NCAPD3, CLCF1, HACE1, NCAPD2, ESR1, SAMHD1, CYP27A1, CCDC88C). This multistep approach highlighted novel RA/PsA candidate genes and genotype-phenotype correlations potentially useful for clinicians in selecting the best therapeutic strategy.
- Published
- 2022
- Full Text
- View/download PDF
33. Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak
- Author
-
Arianna Sonaglia, Rosanna Comoretto, Enrico Pasut, Elena Treppo, Giulia Del Frate, Donatella Colatutto, Alen Zabotti, Salvatore De Vita, and Luca Quartuccio
- Subjects
COVID-19 ,safety ,rheumatic ,autoimmune ,outbreak ,therapy ,Microbiology ,QR1-502 - Abstract
This study aims to explore disease patterns of coronavirus disease (COVID-19) in patients with rheumatic musculoskeletal disorders (RMD) treated with immunosuppressive drugs in comparison with the general population. The observational study considered a cohort of RMD patients treated with biologic drugs or small molecules from September 2019 to November 2020 in the province of Udine, Italy. Data include the assessment of both pandemic waves until the start of the vaccination, between February 2020 and April 2020 (first), and between September 2020 and November 2020 (second). COVID-19 prevalence in 1051 patients was 3.5% without significant differences compared to the general population, and the course of infection was generally benign with 2.6% mortality. A small percentage of COVID-19 positive subjects were treated with low doses of steroids (8%). The most used treatments were represented by anti-TNF agents (65%) and anti-IL17/23 agents (16%). More than two-thirds of patients reported fever, while gastro-intestinal symptoms were recorded in 27% of patients and this clinical involvement was associated with longer swab positivity. The prevalence of COVID-19 in RMD patients has been confirmed as low in both waves. The benign course of COVID-19 in our patients may be linked to the very low number of chronic corticosteroids used and the possible protective effect of anti-TNF agents, which were the main class of biologics herein employed. Gastro-intestinal symptoms might be a predictor of viral persistence in immunosuppressed patients. This finding could be useful to identify earlier COVID-19 carriers with uncommon symptoms, eventually eligible for antiviral drugs.
- Published
- 2022
- Full Text
- View/download PDF
34. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data
- Author
-
Quartuccio, Luca, Zabotti, Alen, Del Zotto, Stefania, Zanier, Loris, De Vita, Salvatore, and Valent, Francesca
- Published
- 2019
- Full Text
- View/download PDF
35. Knuckle pads mimic early psoriatic arthritis
- Author
-
I. Giovannini, S. Zandonella Callegher, E. Errichetti, S. De Vita, and A. Zabotti
- Subjects
Knuckle pads ,Garrod’s nodes ,psoriatic arthritis ,ultrasound ,dermoscopy. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Knuckle pads or Garrod’s nodes are a rare, non-inflammatory condition. They consist of benign, well-circumscribed fibro-adipose tissue over the small joints of hands and feet. Knuckle pads may be under-diagnosed and mistaken for early arthritis. The rheumatologist should perform an accurate differential diagnosis in which he can be helped by ultrasound and by other colleagues, such as the dermatologist. Ultrasound is considered useful in the assessment of the thickening of the subcutaneous tissue, located usually on the extensor site of proximal interphalangeal and metacarpophalangeal hand joints. Dermoscopy may play a role in detecting epidermal and dermal changes. We hereby report the case of a female patient with knuckle pads mimicking psoriatic arthritis.
- Published
- 2021
- Full Text
- View/download PDF
36. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data
- Author
-
Luca Quartuccio, Alen Zabotti, Stefania Del Zotto, Loris Zanier, Salvatore De Vita, and Francesca Valent
- Subjects
Medicine (General) ,R5-920 ,Science (General) ,Q1-390 - Abstract
Risk of hospitalized infections under biologics among patients suffering from chronic inflammatory autoimmune diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PSA), or psoriasis was investigated using administrative data. The hospital discharge records database, the medical prescription database, and the database of exemptions from medical charges were linked at the individual patient level. A cohort of patients diagnosed with RA, SA, PSA, and severe psoriasis from 2006 to 2017 was identified and followed-up to either the end of 2017 or hospitalization with the main discharge diagnosis of infection, death, or they moved out of the region. Multiple Cox regression was used to estimate the hazard ratio (HR) of hospitalization associated with bDMARDs and adjusting for age, sex, Charlson’s Comorbidity Index, calendar year, prescription of steroids, and use of csDMARDs. Use of bDMARDs was treated as a time-dependent variable. A total of 5596 patients diagnosed with RA, AS, or PSA/severe psoriasis were included in the cohort. Overall, 289 (4.2%) were hospitalized due to infection. Time to first use of biological drugs was significantly associated with a 55% increased risk of hospitalization for infections. Thus, large cohorts from administrative databases are useful to support observations from registries and clinical trials. Patients with chronic autoimmune inflammatory diseases are at risk of serious infections when starting biologics. This risk is higher in the elderly or those with comorbidities. Upper and lower respiratory tract infections are the most common infections. Our findings support prevention policies such as vaccination. Keywords: Rheumatoid, Arthritis, Psoriasis, Biologic drug, Tumor necrosis factor, Infection
- Published
- 2019
- Full Text
- View/download PDF
37. Ultrasonographic Assessment for Tenosynovitis in Juvenile Idiopathic Arthritis with Ankle Involvement: Diagnostic and Therapeutic Significance
- Author
-
Sara Della Paolera, Serena Pastore, Alen Zabotti, Alberto Tommasini, and Andrea Taddio
- Subjects
ankle ,juvenile idiopathic arthritis ,ultrasonography ,methotrexate ,biological therapy ,Pediatrics ,RJ1-570 - Abstract
Background: The role of musculoskeletal ultrasound in JIA is still controversial, although there is growing evidence on its utility, especially in the diagnosis of tenosynovitis. Methods: We presented a retrospective cross-sectional study of a group of patients with JIA with ankle swelling followed in a Pediatric Rheumatology Service of a tertiary-level pediatric hospital in Northern Italy during the follow-up period between January 1st 2003 and December 31st 2019. Preliminary results have been presented at the EULAR Congress 2021. We enrolled only patients who underwent msk-US, and we identified those with a clinical and sonographic diagnosis of tenosynovitis. For each patient, we collected data on demographics, clinical characteristics, and therapeutic strategies during the follow-up. Results: On December 31st 2019, 56 swollen ankles of 48 patients were assessed with msk-US. Twenty-two ankles showed sonographic signs of joint synovitis, sixteen ankles presented signs of both joint synovitis and tenosynovitis, and fourteen ankles presented sonographic signs of tenosynovitis only. Overall, tenosynovitis was detected on 27 (56%) out of 48 children with at least a swollen ankle. In 13 patients out of 27 with tenosynovitis (48%), there was no joint synovitis of ankle or foot. Twenty-five patients with tenosynovitis (92%) achieved clinical and radiological remission: seven patients achieved remission of tenosynovitis with methotrexate only, and fifteen patients with biological drugs alone or in combination therapy. Conclusions: We observed that more than half of the patients with ankle swelling presented a tenosynovitis, and about 50% of them did not show sonographic signs of an active joint synovitis. Among patients with tenosynovitis, biological therapy alone or in association with DMARDs showed effectiveness in inducing disease remission.
- Published
- 2022
- Full Text
- View/download PDF
38. Normal-Appearing Salivary Gland Ultrasonography Identifies a Milder Phenotype of Primary Sjögren's Syndrome
- Author
-
Sara Zandonella Callegher, Alen Zabotti, Ivan Giovannini, Elena Treppo, Luca Quartuccio, and Salvatore De Vita
- Subjects
ultrasoud ,salivary gland ,scoring system ,primary Sjogren's syndrome ,follow-up ,managment ,Medicine (General) ,R5-920 - Abstract
Objective: Salivary gland ultrasound (SGUS) is emerging as a valid tool in the management of primary Sjögren's syndrome (pSS). This study aimed to investigate whether pSS patients with normal-appearing or pathological SGUS findings showed different clinical, laboratory, and pathologic pSS-related features, and to compare the results by using two different SGUS scores.Methods: Consecutive pSS patients, according to the ACR-EULAR classification criteria, were evaluated. Salivary glands were scored using the early 1992 score by De Vita et al. and the latest 2019 OMERACT score, both being semiquantitative 0–3 scoring systems focused on ultrasonographic parenchymal inhomogeneity (grades 0 and 1, normal-appearing; grades 2 and 3, pathological). The patients were then divided into two groups: “SGUS normal-appearing” if all the salivary glands had normal-appearing parenchyma (grade 0 or 1), or “SGUS pathological” if the grade was 2 or 3 in at least one salivary gland. The associations between SGUS and pSS-related clinical, laboratory, and pathological features were then investigated in the two groups.Results: One hundred pSS patients were evaluated, the mean age (±SD) was 60.9 ± 12.0 years, and mean disease duration was 11.7 ± 7.2 years. Twenty-nine out of 100 (29%) patients were in the “SGUS normal-appearing” group and 71/100 (71%) were in the “SGUS pathological” group. A normal-appearing SGUS was significantly associated with the absence of anti-La/SSB antibodies (p < 0.001) and normal unstimulated salivary flow rate (p = 0.02) by both univariate and multivariate analyses. By univariate analysis, a normal-appearing SGUS was significantly associated also with the absence of rheumatoid factor (p = 0.002) and of serum monoclonal component (p = 0.003), ESSDAI < 5 (p = 0.03), and with a negative lip biopsy (p = 0.029). No associations were found with other items, including anti-Ro/SSA (p = 0.145), Schirmer's test (p = 0.793), ESSPRI (p = 0.47), and demographic data. No differences in these results were observed by using the two SGUS scoring systems.Conclusion: The SGUS allowed the identification of different phenotypes of pSS, and different SGUS scores focused on salivary gland inhomogeneity may be effective to this end.
- Published
- 2020
- Full Text
- View/download PDF
39. Feasibility of bioethanol production from rice bran
- Author
-
Francieli Begnini Siepmann, Daneysa Lahis Kalschne, Caroline Zabotti, Eder Lisandro de Moraes Flores, Cristiane Canan, and Eliane Colla
- Subjects
Enzymatic hydrolysis ,Ultrasonic treatment ,Protease ,Response surface methodology ,Alcoholic fermentation. ,Agriculture (General) ,S1-972 - Abstract
Rice bran is a by-product of rice production with a high carbohydrate and starch content and the potential for bioethanol production by alcoholic fermentation. This article describes bioethanol production by Saccharomyces cerevisiae from hydrolyzed defatted rice bran (DRB) a rice by-product applying ultrasonic treatment and protease addition, as well as a sequential strategy of experimental design (SEED). In the first Central Composite Rotatable Design (CCRD), the temperature (25-30 °C) and inoculum concentration (0.5-50 g L-1) had positive effects on bioethanol production, while the effect of pH (4.0-6.0) was not significant. In the second CCRD, the temperature (28-35 °C) and inoculum concentration (10-70 g L-1) had negative and positive effects on bioethanol production (p < 0.05). Protease addition (15 µL g-1) increased the conversion of substrate into bioethanol by 76%. The optimized conditions for the production of 40.7 g L-1 bioethanol were a temperature of 31.5 °C and an inoculum concentration of 70 g L-1. Validation in a benchtop bioreactor produced 40.0 g L-1 of bioethanol from hydrolyzed DRB, and the SEED was characterized as a useful tool to improve bioethanol production from DRB. Furthermore, the DRB proved to be a by-product with great potential for bioethanol production, derived from alternative sources not commonly used in human food.
- Published
- 2020
- Full Text
- View/download PDF
40. Salivary Gland Ultrasonography in Sjögren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project
- Author
-
Alen Zabotti, Sara Zandonella Callegher, Annarita Tullio, Arso Vukicevic, Alojzija Hocevar, Vera Milic, Giacomo Cafaro, Marina Carotti, Konstantina Delli, Orazio De Lucia, Diana Ernst, Francesco Ferro, Angelica Gattamelata, Giuseppe Germanò, Ivan Giovannini, Daniel Hammenfors, Malin V. Jonsson, Sandrine Jousse-Joulin, Pierluigi Macchioni, Simone Parisi, Carlo Perricone, Martin Helmut Stradner, Nenad Filipovic, Athanasios G. Tzioufas, Francesca Valent, and Salvatore De Vita
- Subjects
Sjögren's syndrome ,scoring system ,classification criteria ,reliability exercise ,salivary gland ultrasonography ,Medicine (General) ,R5-920 - Abstract
Objectives: Salivary gland ultrasonography (SGUS) is increasingly applied for the management of primary Sjögren's syndrome (pSS). This study aims to: (i) compare the reliability between two SGUS scores; (ii) test the reliability among sonographers with different levels of experience.Methods: In the reliability exercise, two four-grade semi-quantitative SGUS scoring systems, namely De Vita et al. and OMERACT, were tested. The sonographers involved in work-package 7 of the HarmonicSS project from nine countries in Europe were invited to participate. Different levels of sonographers were identified on the basis of their SGUS experience and of the knowledge of the tested scores. A dedicated atlas was used as support for SGUS scoring.Results: Twenty sonographers participated in the two rounds of the reliability exercise. The intra-rater reliability for both scores was almost perfect, with a Light's kappa of 0.86 for the De Vita et al. score and 0.87 for the OMERACT score. The inter-rater reliability for the De Vita et al. and the OMERACT score was substantial with Light's Kappa of 0.75 and 0.77, respectively. Furthermore, no significant difference was noticed among sonographers with different levels of experience.Conclusion: The two tested SGUS scores are reliable for the evaluation of major salivary glands in pSS, and even less-expert sonographers could be reliable if adequately instructed.
- Published
- 2020
- Full Text
- View/download PDF
41. The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions
- Author
-
Idolazzi, Luca, Zabotti, Alen, Fassio, Angelo, Errichetti, Enzo, Benini, Camilla, Vantaggiato, Elisabetta, Rossini, Maurizio, De Vita, Salvatore, and Viapiana, Ombretta
- Published
- 2019
- Full Text
- View/download PDF
42. The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms
- Author
-
Aydin, Sibel Zehra, Bridgewood, Charles, Zabotti, Alen, Girolimetto, Nicolò, and McGonagle, Dennis
- Published
- 2021
- Full Text
- View/download PDF
43. Differential Diagnosis of Inflammatory Arthropathies by Musculoskeletal Ultrasonography: A Systematic Literature Review
- Author
-
Garifallia Sakellariou, Carlo Alberto Scirè, Antonella Adinolfi, Alberto Batticciotto, Alessandra Bortoluzzi, Andrea Delle Sedie, Orazio De Lucia, Christian Dejaco, Oscar Massimiliano Epis, Emilio Filippucci, Luca Idolazzi, Andrea Picchianti Diamanti, Alen Zabotti, Annamaria Iagnocco, and Georgios Filippou
- Subjects
early arthritis ,ultrasonography ,diagnosis ,systematic review ,imaging ,Medicine (General) ,R5-920 - Abstract
Background: Differential diagnosis in early arthritis is challenging, especially early after symptom onset. Several studies applied musculoskeletal ultrasound in this setting, however, its role in helping diagnosis has yet to be clearly defined. The purpose of this work is to systematically assess the diagnostic applications of ultrasonography in early arthritis in order to summarize the available evidence and highlight possible gaps in knowledge.Methods: In December 2017, existing systematic literature reviews (SLR) on rheumatoid arthritis (RA), osteoarthritis (OA), psoriatic arthritis (PsA), polymyalgia rheumatica (PMR), calcium pyrophosphate deposition disease (CPPD), and gout were retrieved. Studies on ultrasound to diagnose the target conditions and detecting elementary lesions (such as synovitis, tenosynovitis, enthesitis, bone erosions, osteophytes) were extracted from the SLRs. The searches of the previous reviews were updated and data from new studies fulfilling the inclusion criteria extracted. Groups of reviewers worked separately for each disease, when possible diagnostic accuracy (sensitivities, specificities) was calculated from primary studies. When available, the reliability of ultrasound to detect elementary lesions was extracted.Results: For all the examined disease, recent SLRs were available. The new searches identified 27 eligible articles, with 87 articles included from the previous SLRs. The diagnostic performance of ultrasound in identifying diseases was addressed by 75 studies; in most of them, a single elementary lesion was used to define diagnosis, except for PMR. Only studies on RA included consecutive patients with new onset of arthritis, while studies on gout and CPPD often focused on subjects with mono-arthritis. Most of the remaining studies enrolled patients with a defined diagnosis. Synovitis was the most frequently detected lesion; clinical diagnosis was the most common reference standard. The diagnostic performance of ultrasound across different conditions was extremely variable. Ultrasound to identify elementary lesions was assessed in 38 studies in OA, gout and CPPD. Its performance in OA was very variable, with better results in CPPD and gout. The reliability of ultrasound was moderate to good for most lesions.Conclusions: Although a consistent amount of literature investigated the diagnostic application of ultrasound, in only a minority of cases its additional value over clinical diagnosis was tested. This SLR underlines the need for studies with a pragmatic design to identify the placement of ultrasound in the diagnostic pathway of new-onset arthritis.
- Published
- 2020
- Full Text
- View/download PDF
44. Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
- Author
-
Salvatore D'Angelo, Fabrizio Cantini, Roberta Ramonda, Luca Cantarini, Antonio Carletto, Maria Sole Chimenti, Andrea Delle Sedie, Rosario Foti, Roberto Gerli, Claudia Lomater, Ennio Lubrano, Antonio Marchesoni, Alen Zabotti, Carlo Salvarani, Rossana Scrivo, Raffaele Scarpa, Giuseppina Tramontano, Carlotta Nannini, Mariagrazia Lorenzin, Marta Fabbroni, Federica Martinis, Roberto Perricone, Linda Carli, Elisa Visalli, Guido Rovera, Fabio Massimo Perrotta, Luca Quartuccio, Alessio Altobelli, Luisa Costa, Laura Niccoli, Augusta Ortolan, and Francesco Caso
- Subjects
psoriatic arthritis ,biological drugs ,adalimumab ,retention rate ,real-life ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated.Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate.Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2–3.2, p = 0.005).Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.
- Published
- 2019
- Full Text
- View/download PDF
45. Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study
- Author
-
Antonio Marchesoni, Pierluigi Macchioni, Stefania Gasparini, Carlo Perricone, Fabio Massimo Perrotta, Rosa Daniela Grembiale, Ettore Silvagni, Roberta Ramonda, Luisa Costa, Alen Zabotti, Giacomo Curradi, Giuliana Gualberti, Francesca Marando, and Carlo Salvarani
- Subjects
ultrasound ,B mode ,power Doppler ,psoriatic arthritis ,fibromyalgia syndrome ,diagnosis ,Medicine - Abstract
In psoriatic arthritis (PsA) patients with concomitant chronic widespread pain, the differential diagnosis with fibromyalgia syndrome (FMS) can be challenging. We evaluated whether ultrasound (US) examination of entheseal sites can distinguish pain from (PsA) enthesitis versus FMS. PsA and FMS patients underwent clinical evaluation and gray-scale (GS; B-mode) and power Doppler (PD) US examination of the entheses. At least one enthesis with GS- and PD-mode changes was found in 90% and 59.3% of PsA patients (n = 140) and 62.7% and 35.3% of FMS patients (n = 51), respectively. GS and PD identified changes in 49.5% and 19.2% of the 840 PsA entheses and 22.5% and 7.9% of the 306 FMS entheses, respectively. Receiver operating characteristic curve analysis showed an area under the curve of 0.77 and 0.66 for B- and PD-mode, respectively, 3.5 being the best cut-off GS-score to discriminate the two conditions. Multivariate regression showed that Achilles and proximal patellar tendon enthesitis (B-mode) were strongly associated with PsA (odds ratio, ~2). Principal component analysis (B-mode) confirmed that PsA patients have a higher number of involved entheses and patterns of entheseal involvement than FMS patients. US evaluation of the entheses may help differentiate chronic widespread pain from PsA versus FMS.
- Published
- 2021
- Full Text
- View/download PDF
46. From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention
- Author
-
Zabotti, Alen, Tinazzi, Ilaria, Aydin, Sibel Zehra, and McGonagle, Dennis
- Published
- 2020
- Full Text
- View/download PDF
47. Post-COVID-19 Arthritis and Sacroiliitis: Natural History with Longitudinal Magnetic Resonance Imaging Study in Two Cases and Review of the Literature
- Author
-
Donatella Colatutto, Arianna Sonaglia, Alen Zabotti, Lorenzo Cereser, Rossano Girometti, and Luca Quartuccio
- Subjects
sacroiliitis ,arthritis ,COVID-19 ,post-COVID-19 manifestations ,Microbiology ,QR1-502 - Abstract
Severe acute respiratory coronavirus-2 syndrome (SARS-CoV-2) is a well-known pandemic infectious disease caused by an RNA virus belonging to the coronaviridae family. The most important involvement during the acute phase of infection concerns the respiratory tract and may be fatal. However, COVID-19 may become a systemic disease with a wide spectrum of manifestations. Herein, we report the natural history of sacroiliac inflammatory involvement in two females who developed COVID-19 infection with mild flu-like symptoms. After the infection they reported inflammatory back pain, with magnetic resonance imaging (MRI) studies showing typical aspects of sacroiliitis. Symptoms improved with NSAIDs therapy over the following months while MRI remained positive. A literature review was performed on this emerging topic. To our knowledge, this is the first MRI longitudinal study of post-COVID-19 sacroiliitis with almost one year of follow-up. Predisposing factors for the development of articular involvement are unclear but a long-lasting persistence of the virus, demonstrated by nasopharyngeal swab, may enhance the probability of altering the immune system in a favourable background.
- Published
- 2021
- Full Text
- View/download PDF
48. Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging
- Author
-
Nicolò Girolimetto, Ivan Giovannini, Gloria Crepaldi, Gabriele De Marco, Ilaria Tinazzi, Niccolò Possemato, Pierluigi Macchioni, Rebecca McConnell, Dennis McGonagle, Annamaria Iagnocco, and Alen Zabotti
- Subjects
dactylitis ,psoriatic arthritis ,ultrasound ,imaging ,score ,Medicine - Abstract
Dactylitis, one of the most typical features of psoriatic arthritis (PsA), is the diffuse swelling of the digits and is determined by the involvement of different anatomic structures, including: the subcutaneous fibrous tissue “accessory pulley” system; flexor tendons, with their related structures; the articular synovium; the small enthesis of the hands. Dactylitis is currently considered both a marker of disease activity and severe prognosis and its importance in PsA is emphasized by the inclusion in the classification criteria of PsA. This review focuses on the role of imaging in the management of PsA patients with dactylitis in clinical practice and in a research setting. Furthermore, imaging could be a valuable tool to assist in unravelling some of the underlying mechanisms of the onset and chronicization of dactylitis in PsA patients.
- Published
- 2021
- Full Text
- View/download PDF
49. Axial Psoriatic Disease: Clinical and Imaging Assessment of an Underdiagnosed Condition
- Author
-
Ivan Giovannini, Alen Zabotti, Carmelo Cicciò, Matteo Salgarello, Lorenzo Cereser, Salvatore De Vita, and Ilaria Tinazzi
- Subjects
axial psoriatic arthritis ,psoriatic arthritis ,stiffness ,inflammatory back pain ,Medicine - Abstract
The frequent involvement of the spine and sacroiliac joint has justified the classification of psoriatic arthritis (PsA) in the Spondyloarthritis group. Even if different classification criteria have been developed for PsA and Spondyloarthritis over the years, a well-defined distinction is still difficult. Although the majority of PsA patients present peripheral involvement, the axial involvement needs to be taken into account when considering disease management. Depending on the definition used, the prevalence of axial disease may vary from 25 to 70% in patients affected by PsA. To date, no consensus definition has been reached in the literature and the definition of axial involvement in PsA has varied from isolated sacroiliitis to criteria used in ankylosing spondylitis. This article reviews the unmet needs in the clinical and radiological assessment of axial PsA, reporting the various interpretations of axial involvement, which have changed over the years. Focusing on both imaging and clinical standpoints, we reported the prevalence of clinical and radiologic features, describing the characteristics of axial disease detectable by X-rays, magnetic resonance imaging, and PET-CT, and also describing the axial symptoms and outcome measures in patients affected by axial disease.
- Published
- 2021
- Full Text
- View/download PDF
50. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors
- Author
-
Luca Quartuccio, Saviana Gandolfo, Alen Zabotti, Sara Zandonella Callegher, Cinzia Fabro, and Salvatore De Vita
- Subjects
primary Sjögren's syndrome ,extraglandular involvement ,disease activity ,peripheral nervous system ,ESSDAI ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objective: The disease course in primary Sjögren's Syndrome (pSS) differs in different subsets of patients. The aim of this study was to clarify whether the pattern of organ involvement may improve the prediction of the very long-term disease outcome.Methods: We collected the data of 255 patients. The total European League Against Rheumatism (EULAR), EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score was compared with the pattern of organ involvement, as differentiated by the single ESSDAI domains: (i) at disease diagnosis, and (ii) in the follow-up, by verifying the appearance of new ESSDAI domains and/or the worsening of already active ESSDAI domains.Results: The mean follow-up duration was 9.1 ± 6.9 years. At disease diagnosis, only the articular activity at baseline could predict the long-term outcome of pSS detected at last follow-up visit, being protective in terms of stable or improved disease activity, as measured by ESSDAI [OR 2.9 (1.6–5.4), p = 0.01]. In the follow-up, the onset, and/or worsening of either the peripheral nervous system (PNS) domain (by multivariate and univariate analysis), or the biological domain (only by univariate analysis) correlated with a higher disease activity at the last visit [PNS domain: OR 5.9 (2.4–14.5), p < 0.0001; biological domain: OR 1.9 (1.0–3.8), p = 0.043]. A significantly higher number of patients with articular involvement were taking hydroxychloroquine at the last follow-up visits, if compared with patients without (41/130, 31.5 vs. 13/125, 10.4%, p < 0.0001).Conclusion: Single organ disease manifestations of SS, herein identified as the articular, PNS and biologic involvement, are relevant to predict the very long-term outcome in pSS.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.